Clin Osteol 2010; 15(4): 136-141

Cinacalcet hydrochloride - current therapeutic useReview articles

J. Lazarová

Cinacalcet hydrochloride represents a major breakthrough in the treatment ofboth primary and secondary hyperparathyroidism. This review aims to summarize current knowledge on cinacalcet hydrochloride therapeutic indications and use.

Keywords: cinacalcet hydrochloride, calcium sensing receptor, parathyroid hormone, hyperparathyroidism

Published: December 11, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lazarová J. Cinacalcet hydrochloride - current therapeutic use. Osteologický bulletin. 2010;15(4):136-141.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Brown EM et al. Cloning and characterization of an extracellular Ca2+ -sensing re­ ceptor from bovine parathyroid. Nature 1993;366:575-580. Go to original source...
    2. Brown EM. Calcium receptor and regulation of parathyroid hormone secretion. Rev Endocrinol Metab Dis 2000;1:307-315. Go to original source...
    3. Tfelt-Hansen J, Brown EM. The calcium-sensing receptor in normal physiology and pathophysiology: a review. Crit Rev Clin Lab Sci 2005;42:35-70. Go to original source...
    4. Brown EM. The Calcium sensing receptor: Physiology and pathophysiology and CaR-based therapeutics. Sub-Cellular Biochemistry 2007;139-167. Go to original source...
    5. Ziyad Al-Aly. The new role of calcimimetics as vasculotropic agents. Kidney International 2009;75:9-12. Go to original source...
    6. Nemeth EF et al. Calcimimetics with potent and selective activity on the parathy­ roid calcium receptor. Proc Natl Acad Sci USA 1998;95:4040-4045. Go to original source...
    7. Brown EM et al. A comparison of the effect of divalent and trivalent cationts on parathyroid hormone release. 3'5'-cyclic-adenosine monophosphate accumulati­ on, and the levels of inositol phosphates in bovine parathyroid cells. Endocrinology 1990;127:1064-1071. Go to original source...
    8. Nemeth E, Scarpa A. Rapid mobilization of cellular Ca2+ in bovine parathyroid cells by external divalent cations. J Biol Chem 1987;262:5188-5196. Go to original source...
    9. Shoback DM et al. High calcium and other divalent cations increase inositol tri­ phosphate in bovine parathyroid cells. Endocrinology 1988;123:382-389. Go to original source...
    10. Quinn SJ et al. The Ca2+ -sensing receptor: a target for polyamides. Am J Physiol Cell Physiol 1997;273:C1315-1323. Go to original source...
    11. Ye C et al. Amyloid-beta proteins activate Ca2+ -permeable channels through cal­ cium-sensing receptors. J Neurosci Res 1997;47:547-554. Go to original source...
    12. Goodman WG et al. A calcimimetic agent lowers plasma parathyroid hormone le­ vels in patients with secondary hyperparathyroidism. Kidney Int 2000;58:436-445. Go to original source...
    13. Slatopolsky E et al. Pathogenesis of secondary hyperparathyreoidism. Kidney Int 1999; 56 (suppl.73):S14-S19. Go to original source...
    14. Dusilová-Sulková S. Renální osteopatie. Praha, Maxdorf, 2007.
    15. Silver J. Molecular mechanism of secondary hyperparathyroidism. Nephrol Dial Transplant 2000; 15 (Suppl.5):S2-S7. Go to original source...
    16. Ritter CS et al. Reversal of secondary hyperparathyroidism by phosphate restricti­ on restores parathyroid calcium-sensing receptor expression and function. J Bone Miner Res 2002;17:2206-2213. Go to original source...
    17. Nemeth EF et al. Pharmacodynamics of the typ II calcimimetics compound cinacalcet HCL. J Pharmacol Exp Ther 2004;308:627-635. Go to original source...
    18. Valle C et al. Cinacalcet reduces the set point ofthe PTH-calcium curve. J Am Soc Nephrol 2008;19:2430-2436. Go to original source...
    19. Block GA The impact of calcimimetics on mineral metabolism and secondary hy­ perparathyroidism in end-stage renal disease. Kidney Int 2003; 64 (Suppl87): S131-S136. Go to original source...
    20. SmPC Cinacalcet, Amgen Inc.
    21. De Francisco ALM et al. Oral cinacalcet HCl (AMG 073) for the treatment of hemodialysis patients with secondary hyperparathyroidism: results of a European/Australian Phase 3 study (abstract SA-PO742). J Am Soc Nephrol 2003;14:461A
    22. Block GA et al. Phase 3 study results demonstrate efficacy and safety of the cal­ cimimetic cinacalcet HCl in hemodialysis patients with secondary hyperparathy­ roidism (abstract SA-PO743). J Am Soc Nephrol 2003;14:461A
    23. Moe SM et al. Achieving NKF-K/DOQI™ bone metabolism and disease treatment goals with cinacalcet HCL. Kidney int 2005; 67:760-771. Go to original source...
    24. Chertow GM et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): Rationale and Design Overview. Clin J Am Soc Nephrol. 2007;2:898-905. Go to original source...
    25. Floege J, Raggi P, Block GA, Torres PU, Csiky B, Naso A, Nossuli, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Chertow GM. ADVANCE Study group. Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2010 Jun; 25(6):1916-23. Epub 2010 Jan 27. Go to original source...
    26. Messa P et al. The OPTIMA Study: Assessing a New Cinacalcet (Sensipar/Mimpara) Treatment Algorithm for Secondary Hyperparathyroidism. Clin J Am Soc Nephrol 2008;3:36 45. Go to original source...
    27. Vervloet M et al. Cinacalcet increased KDOQI TM Goal Achievment in "Real World" Clinical Practice (ECHO study). ASN 2007; Abstract SU-FC098.
    28. Sosa JA, Udelsman R. New directions in the treatment of patients with primary hyperparathyroidism. Curr Probl Surg 2003;40:812-849. Go to original source...
    29. Adami S et al. Epidemiology of primary hyperparathyroidism in Europe. J Bone Min Res 2002;17 (Suppl 2):N18-N23.
    30. Bilezikian JP et al. Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med 2005;257:6-17. Go to original source...
    31. Peacock M et al. Cinacalcet Hydrochloride Maintains Long-Term Normocalcemia in Patients with Primary Hyperparathyroidism. J Clin Endocrinol Metab 2005; 90:135-141. Go to original source...
    32. Peacock M et al. Cinacalcet Treatment of Primary Hyperparathyroidism: Biochemical and Bone Densitometric Outcomes in a Five-Year Study. J Clin Endocirnol Metab 2009;94:4860 4867. Go to original source...
    33. Marcocci C et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism, J Clin Endocrinol Metab 2009;94:2766-2772. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.